These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1719718)

  • 1. [The serological characteristics of the O antigens of Pseudomonas aeruginosa isolated from patients with a Pseudomonas infection during immunotherapy].
    Kholodkova EV; Krylov VM; Badikov VD; Sukhovskaia OA; Bazanova EB; Iushkova NA; Stanislavskiĭ ES
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Aug; (8):59-61. PubMed ID: 1719718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advisability of using donor blood immunoglobulin preparations for treating infections caused by Pseudomonas aeruginosa].
    Nazarchuk LV
    Klin Khir (1962); 1991; (1):23-4. PubMed ID: 1712409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy.
    Stanislavsky ES; Dmitriev BA; Lányi B; Joó I
    Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389
    [No Abstract]   [Full Text] [Related]  

  • 4. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
    Pennington JE; Pier GB; Sadoff JC; Small GJ
    Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serotyping strains of Pseudomonas aeruginosa].
    Smirnova NE
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Sep; (9):126-9. PubMed ID: 827883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slime glycolipoproteins and the pathogenicity of various strains of Pseudomonas aeruginosa in experimental infection.
    Dimitracopoulos G; Bartell PF
    Infect Immun; 1980 Nov; 30(2):402-8. PubMed ID: 6777303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological study of Pseudomonas aeruginosa extracellular slime.
    Stanislavsky ES; Yushkova NA; Edvabnaya LS; Landsman NM; Zaidner IG
    Acta Microbiol Hung; 1985; 32(1):49-59. PubMed ID: 2412390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the protective properties of antisera and immunoglobulin to antigens of Pseudomonas aeruginosa slime].
    Zaĭdner IG; Stanislavskiĭ ES; Gladus MA
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Oct; (10):52-7. PubMed ID: 6778023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
    Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
    Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extraction and characteristics of agglutinating sera to the O-antigens of Pseudomonas aeruginosa].
    Smirnova NE; Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Mar; 0(3):119-22. PubMed ID: 804787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
    Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunoprophylaxis and immunotherapy of experimental Pseudomonas aeruginosa sepsis].
    Grishina IA; Terekhova RP; Marchuk AI
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):14-7. PubMed ID: 3087118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
    Neely AN; Holder IA
    Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative study of the antibody concentration and protective activity against Pseudomonas aeruginosa of gamma-globulin and IgM-enriched immunoglobulin preparations].
    Kiseleva IA; Kandiurina VG; Timofeeva GV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):68-71. PubMed ID: 2424197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.